A Phase I, Double Blind, Randomized, Two-Way Cross Over, Single- Centre Study in Healthy CYP2D6 Extensive Metabolizers and Poor Metabolizers to Investigate the Potential of AZD3480 [ispronicline] to Inhibit Cytochrome P450 1A2, 2C19, 3A4, 2C8, 2B6, and UGT1A1 Activity

Trial Profile

A Phase I, Double Blind, Randomized, Two-Way Cross Over, Single- Centre Study in Healthy CYP2D6 Extensive Metabolizers and Poor Metabolizers to Investigate the Potential of AZD3480 [ispronicline] to Inhibit Cytochrome P450 1A2, 2C19, 3A4, 2C8, 2B6, and UGT1A1 Activity

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2010

At a glance

  • Drugs Ispronicline (Primary) ; Bilirubin oxidase inhibitors; Bupropion; Caffeine; Midazolam; Omeprazole; Rosiglitazone
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Nov 2008 Status changed from recruiting to completed, as reported in ClinicalTrials.gov record.
    • 24 Sep 2008 Planned end date changed from 1 Jul 2008 to 1 Sep 2008 as reported by CT.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top